Site-Directed Combination Chemotherapy
In the treatment of human neoplasia, major biological problems present obstacles which make the cure of human cancer difficult. These problems center around the heterogeneous nature of a tumor cell population and the invasive and metastatic potential of this tumor cell population (1–3). The major forms of cancer treatment involve the modalities of surgery, radiation therapy and chemotherapy. In many cases, combinations of these treatment-forms are used sequentially in an attempt to deal with the problems of metastasis and heterogeneity of tumor cells. Results of current research suggest that biotherapy (use of immune regulators, differentiation inducers, etc.) may also provide an additional mode of treatment.
KeywordsAdenosine Deaminase Ribonucleotide Reductase Tumor Cell Population Purine Nucleoside Phosphorylase Ribonucleotide Reductase Inhibitor
Unable to display preview. Download preview PDF.
- 4.A. C. Sartorelli and W. A. Creasey, Combination Chemotherapy, in: “Cancer Medicine,” J. F. Holland and E. Frei, III, eds., Lea and Febiger, Philadelphia (1982).Google Scholar
- 5.R. H. Blum and E. Frei, III, Combination Chemotherapy, in: “Methods in Cancer Research,” Volume XVII, V. T. DeVita, Jr., and H. Busch, eds., Academic Press, New York (1979).Google Scholar
- 16.J. G. Cory, D. A. Rey, G. L. Carter, and P. E. Bacon, Nucleoside 5’-Diphosphates as Effectors of Mammalian Ribonucleotide Reductase, J. Biol. Chem. 260: 1201 (1985).Google Scholar
- 19.J. A. Montgomery, The Biological Bases for the Design of Anticancer Agents, in: “Cancer Biology and Therapeutics,” J. G. Cory and A. Szentivanyi, eds., Plenum Press, New York (1986).Google Scholar
- 27.J. A. Montgomery, The Chemistry and Biology of Nucleosides of Purines and Ring Analogs, in: “Proceedings of the Fifth International Roundtable on Nucleosides, Nucleotides, and their Biological Applications,” Academic Press, New York (1983).Google Scholar